When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

1 Day NVO 1.74% DJIA -0.36% S&P 500 -0.22% Health Care/Life Sciences -0.02% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...